Robert F. Kennedy Jr.’s appointment last month to lead the U.S. Department of Health and Human Services immediately sent ...

After a rough few months for Intercept and Advanz Pharma's Ocaliva on both sides of the Atlantic, the other shoe has dropped for the rare liver disease drug in Europe. | The General Court of the ...

Belgium mRNA specialist Quantoom Biosciences and biologics manufacturing specialist Univercells inked a partnership deal with ...

The FDA notification came seven weeks after the New England Journal of Medicine (NEJM) published a report that seven of 67 ...

Shortly after a similarly sized venture from Pfizer, French pharma juggernaut Sanofi has unveiled a major manufacturing ...

GSK has brought its message about the risks of antimicrobial resistance (AMR) to commuters in London. | GSK has brought its ...

Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...

| Takeda is focused on curbing dengue with innovative solutions and public-private partnerships to achieve the WHO’s goal of ...

Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will have to first face the agency’s Oncologic Drugs Advisory Committee ( | The ...

Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer antidepressant, reduced bouts of cataplexy and other narcolepsy symptoms in ...